EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation

被引:0
|
作者
Miriam Sanchez-Escamilla
Jessica Flynn
Sean Devlin
Molly Maloy
Samira A. Fatmi
Ana Alarcon Tomas
Silvia Escribano-Serrat
Doris Ponce
Craig S. Sauter
Sergio A. Giralt
Michael Scordo
Miguel-Angel Perales
机构
[1] Memorial Sloan Kettering Cancer Center,Adult Bone Marrow Transplantation Service, Department of Medicine
[2] Memorial Sloan Kettering Cancer Center,Department of Epidemiology and Biostatistics
[3] Research Institute of Marques de Valdecilla (IDIVAL),Department of Hematological Malignancies and Stem Cell Transplantation
[4] Weill Cornell Medical College,Department of Medicine
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The Endothelial Activation and Stress Index (EASIX) is a prognostic tool that uses common clinical laboratory values and has been shown to predict non-relapse mortality (NRM) and overall survival (OS) at the onset of acute graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT). We hypothesized that EASIX calculated at different time points pre- and post- HCT may predict NRM and OS, and that EASIX calculated at onset of GVHD may predict response to steroids. We evaluated the EASIX score pre- and post-HCT in 152 patients with lymphoid malignancies undergoing unmodified reduced intensity conditioning (RIC) alloHCT with uniform GVHD prophylaxis. In multivariate analysis, EASIX calculated pre-HCT was significantly associated with higher NRM (HR = 1.64, p = 0.009) and lower OS (HR = 1.33, p = 0.046). Furthermore, EASIX calculated at day 30 and at day 100 was associated with increased NRM (HR = 1.65, p < 0.001; and HR = 1.65, p < 0.001) and decreased OS (HR = 1.27, p = 0.018; and HR = 1.49, p < 0.001), independent of HCT-CI, disease and conditioning regimen. Our study shows that high EASIX scores at various time points pre- and post-HCT are significantly associated with poorer overall outcomes. EASIX provides an independent and easily accessible tool to predict outcomes that can be complementary to other measures of risk stratification for patients undergoing HCT.
引用
收藏
页码:498 / 505
页数:7
相关论文
共 50 条
  • [1] EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation
    Sanchez-Escamilla, Miriam
    Flynn, Jessica
    Devlin, Sean
    Maloy, Molly
    Fatmi, Samira A.
    Tomas, Ana Alarcon
    Escribano-Serrat, Silvia
    Ponce, Doris
    Sauter, Craig S.
    Giralt, Sergio A.
    Scordo, Michael
    Perales, Miguel-Angel
    BONE MARROW TRANSPLANTATION, 2023, 58 (05) : 498 - 505
  • [2] Prognostic Value of EASIX Score in Allogeneic Hematopoietic Stem Cell Transplantation
    Faleschini, Juliana
    Colombo, Evelyn
    Jarchum, Sol
    Meneces, Rodrigo
    Rocca, Malena
    Jarchum, Gustavo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S305 - S305
  • [3] EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation
    Tolosa-Ridao, Carles
    Cascos, Enric
    Rodriguez-Lobato, Luis Gerardo
    Pedraza, Alexandra
    Suarez-Lledo, Maria
    Charry, Paola
    Solano, Maria Teresa
    Martinez-Sanchez, Julia
    Cid, Joan
    Lozano, Miquel
    Rosinol, Laura
    Esteve, Jordi
    Urbano-Ispizua, Alvaro
    Fernandez-Aviles, Francesc
    Martinez, Carmen
    Carreras, Enric
    Diaz-Ricart, Maribel
    Rovira, Montserrat
    Salas, Maria Queralt
    BONE MARROW TRANSPLANTATION, 2024, 59 (07) : 974 - 982
  • [4] Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation
    Pena, Marta
    Queralt Salas, Maria
    Mussetti, Alberto
    Moreno-Gonzalez, Gabriel
    Bosch, Anna
    Patino, Beatriz
    Jimenez, Laura
    Kara, Meriem
    Parody, Rocio
    Sureda, Anna
    BLOOD ADVANCES, 2021, 5 (17) : 3418 - 3426
  • [5] EASIX SCORE AS INDEPENDENT PREDICTOR FOR OVERALL SURVIVAL IN PATIENTS WITH ACUTE LEUKEMIA AND MDS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
    Ganeva, Penka
    Bankova, Andriyana
    Vasilev, Georgi
    Venkov, Krasen
    Milcheva, Kameliya
    Yankova, Victoria
    Guenova, Margarita
    Mihaylov, Georgi
    BONE MARROW TRANSPLANTATION, 2024, 59 : 568 - 569
  • [6] Easix before Conditioning Therapy Predicts Sepsis after Allogeneic Stem Cell Transplantation
    Korell, Felix
    Schreck, Nicholas
    Benner, Axel
    Liebregts, Tobias
    Schoenland, Stefan
    Hegenbart, Ute
    Radujkovic, Aleksandar
    Schmitt, Michael
    Dreger, Peter
    Luft, Thomas
    BLOOD, 2021, 138 : 1774 - +
  • [7] EASIX and mortality after allogeneic stem cell transplantation
    Thomas Luft
    Axel Benner
    Tobias Terzer
    Sonata Jodele
    Christopher E. Dandoy
    Rainer Storb
    Lambros Kordelas
    Dietrich Beelen
    Ted Gooley
    Brenda M. Sandmaier
    Mohamed Sorror
    Markus Zeisbrich
    Aleksandar Radujkovic
    Peter Dreger
    Olaf Penack
    Bone Marrow Transplantation, 2020, 55 : 553 - 561
  • [8] EASIX and mortality after allogeneic stem cell transplantation
    Luft, Thomas
    Benner, Axel
    Terzer, Tobias
    Jodele, Sonata
    Dandoy, Christopher E.
    Storb, Rainer
    Kordelas, Lambros
    Beelen, Dietrich
    Gooley, Ted
    Sandmaier, Brenda M.
    Sorror, Mohamed
    Zeisbrich, Markus
    Radujkovic, Aleksandar
    Dreger, Peter
    Penack, Olaf
    BONE MARROW TRANSPLANTATION, 2020, 55 (03) : 553 - 561
  • [9] Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients
    Huang, Li-Wen
    Sheng, Ying
    Andreadis, Charalambos
    Logan, Aaron C.
    Mannis, Gabriel N.
    Smith, Catherine C.
    Gaensler, Karin M. L.
    Martin, Thomas G.
    Damon, Lloyd E.
    Steinman, Michael A.
    Huang, Chiung-Yu
    Olin, Rebecca L.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (01) : 189 - 196
  • [10] Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation
    Nawas, Mariam T.
    Sanchez-Escamilla, Miriam
    Devlin, Sean M.
    Maloy, Molly A.
    Ruiz, Josel D.
    Sauter, Craig S.
    Giralt, Sergio A.
    Perales, Miguel-Angel
    Scordo, Michael
    BLOOD ADVANCES, 2022, 6 (22) : 5898 - 5907